Authors:
Moldrich, RX
Talebi, A
Beart, PM
Chapman, AG
Meldrum, BS
Citation: Rx. Moldrich et al., The mGlu(2/3) agonist 2R,4R-4-aminopyrrolidine-2,4-dicarboxylate, is anti-and proconvulsant in DBA/2 mice, NEUROSCI L, 299(1-2), 2001, pp. 125-129
Citation: Sf. Giardina et Pm. Beart, Excitotoxic profiles of novel, low-affinity kainate receptor agonists in primary cultures of murine cerebellar granule cells, NEUROPHARM, 41(4), 2001, pp. 421-432
Authors:
Moldrich, RX
Jeffrey, M
Talebi, A
Beart, PM
Chapman, AG
Meldrum, BS
Citation: Rx. Moldrich et al., Anti-epileptic activity of group II metabotropic glutamate receptor agonists (-)-2-oxa-4-aminobicyclo[3.1.0]hexane-4,6-dicarboxylate (LY379268) and (-)-2-thia-4-aminobicyclo[3.1.0]hexane-4,6-dicarboxylate (LY389795), NEUROPHARM, 41(1), 2001, pp. 8-18
Citation: Rx. Moldrich et al., Group II mGlu receptor agonists fail to protect against various neurotoxicinsults induced in murine cortical, striatal and cerebellar granular pure neuronal cultures, NEUROPHARM, 41(1), 2001, pp. 19-31
Authors:
Aprico, K
Beart, PM
Lawrence, AJ
Crawford, D
O'Shea, RD
Citation: K. Aprico et al., [H-3](2S,4R)-4-methylglutamate: a novel ligand for the characterization ofglutamate transporters, J NEUROCHEM, 77(5), 2001, pp. 1218-1225
Authors:
Callaway, JK
Beart, PM
Jarrott, B
Giardina, SF
Citation: Jk. Callaway et al., Incorporation of sodium channel blocking and free radical scavenging activities into a single drug, AM-36, results in profound inhibition of neuronalapoptosis, BR J PHARM, 132(8), 2001, pp. 1691-1698
Citation: Ld. Mercer et al., Direct visualization of cholecystokinin subtype2 receptors in rat central nervous system using anti-peptide antibodies, NEUROSCI L, 293(3), 2000, pp. 167-170
Authors:
Callaway, JK
Knight, MJ
Watkins, DJ
Beart, PM
Jarrott, B
Delaney, PM
Citation: Jk. Callaway et al., A novel, rapid, computerised method for quantitation of neuronal damage ina rat model of stroke, J NEUROSC M, 102(1), 2000, pp. 53-60
Citation: Kj. Crossley et al., Characterisation of GABA(A) receptors in fetal, neonatal and adult ovine brain: region and age related changes and the effects of allopregnanolone, NEUROPHARM, 39(9), 2000, pp. 1514-1522
Authors:
Moldrich, RX
Cheung, NS
Pascoe, CJ
Baker, SR
Pedregal, C
Beart, PM
Citation: Rx. Moldrich et al., Excitotoxic profile of LY339434, a GluR5 agonist, in cultured murine cortical neurons, BRAIN RES, 862(1-2), 2000, pp. 270-275
Authors:
John, CA
Beart, PM
Giardina, SF
Pascoe, CJ
Cheung, NS
Citation: Ca. John et al., Cyclothiazide and GYKI 52466 modulate AMPA receptor-mediated apoptosis in cortical neuronal cultures, NEUROSCI L, 268(1), 1999, pp. 9-12
Authors:
Jarrott, B
Callaway, JK
Jackson, WR
Beart, PM
Citation: B. Jarrott et al., Development of a novel arylalkylpiperazine compound (AM-36) as a hybrid neuroprotective drug, DRUG DEV R, 46(3-4), 1999, pp. 261-267
Authors:
Callaway, JK
Knight, MJ
Watkins, DJ
Beart, PM
Jarrott, B
Citation: Jk. Callaway et al., Delayed treatment with AM-36, a novel neuroprotective agent, reduces neuronal damage after endothelin-1-induced middle cerebral artery occlusion in conscious rats, STROKE, 30(12), 1999, pp. 2704-2712
Citation: Nm. Jones et al., Type I and II metabotropic glutamate receptors mediate depressor and bradycardic actions in the nucleus of the solitary tract of anaesthetized rats, EUR J PHARM, 380(2-3), 1999, pp. 129-135
Authors:
Li, XC
Beart, PM
Monn, JA
Jones, NM
Widdop, RE
Citation: Xc. Li et al., Type I and II metabotropic glutamate receptor agonists and antagonists evoke cardiovascular effects after intrathecal administration in conscious rats, BR J PHARM, 128(3), 1999, pp. 823-829